查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012665

過敏疫苗市場：2026-2032年全球市場預測（依疫苗類型、給藥途徑、目標過敏原、技術、病患年齡層、最終用戶和分銷管道分類）

Allergy Vaccine Market by Vaccine Type, Route Of Administration, Allergens Targeted, Technology, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，過敏疫苗市場價值將達到 16 億美元，到 2026 年將成長到 17.9 億美元，到 2032 年將達到 39 億美元，複合年成長率為 13.58%。

主要市場統計數據
基準年 2025 16億美元
預計年份：2026年 17.9億美元
預測年份 2032 39億美元
複合年成長率 (%) 13.58%

簡要介紹影響過敏疫苗研發和分銷的臨床、營運和商業性因素。

目前，過敏疫苗領域正經歷快速創新的時期，免疫生物學、遞送技術和支付方期望等方面的進步相互交織。近期臨床進展使人們更加關注患者的持續療效和安全性，同時，製劑和給藥方式的改善也拓寬了可行的治療模式。因此，相關人員不僅要評估其科學價值，還要考慮病患依從性、臨床基礎設施和監管途徑等實際因素。

分析科學、患者體驗和數位健康趨勢的融合如何重新定義過敏疫苗的研發、交付和評估方式。

過敏疫苗領域正經歷一場變革，其驅動力源於免疫療法科學、以患者為中心的照護以及數位醫療應用等趨勢的融合。免疫學研究的進步使得抗原設計和佐劑選擇能夠最佳化，從而誘導靶向且持久的免疫反應，同時最大限度地減少不利事件。同時，患者的期望也在改變。易用性、減少就醫次數以及更可預測的副作用正成為產品價值提案的關鍵要素。

近期關稅趨勢如何重塑過敏疫苗生產和分銷的供應鏈韌性、籌資策略和策略決策。

2025年關稅的引入和實施對過敏疫苗生態系統中的企業產生了複雜的營運和策略影響。關稅帶來的成本壓力波及整個供應鏈，影響原料、添加劑及生產設備的採購決策。因此，製造商和經銷商需要重新評估其供應商配置和庫存策略，以減輕成本突然波動的影響，並確保關鍵投入品的穩定供應。

詳細的細分見解解釋了給藥途徑、目標過敏原、疫苗形式、分發方法和使用者環境如何驅動差異化的臨床和商業策略。

細分市場層面的趨勢揭示了通往臨床和商業性成功的多種途徑，給藥途徑、目標過敏原、疫苗劑型、分銷管道、技術平台、患者群體和最終用戶等因素都對營運和價值創造產生特定影響。皮下注射和舌下免疫療法的給藥途徑差異會改變臨床工作流程和患者依從性預期。皮下注射療法給藥間隔較短，需要完善的臨床基礎設施和訓練有素的醫護人員，而標準給藥方案則更著重於長期依從性計畫。舌下療法，包括輸注和片劑，拓展了居家啟動和持續治療的可能性，並將重點轉移到患者教育和遠端監測上，以確保療效的持續性。

區域趨勢和實際考慮因素使得在不同的醫療保健環境中，需要製定模組化的全球策略來協調監管環境、支付方和分銷重點。

區域需求趨勢、監管方面的細微差異以及醫療服務體系的差異，顯著影響過敏疫苗計畫在區域層面的實施方式。在美洲，醫療體系融合了公立和私立保險公司，並擁有多元化的醫療服務提供者網路，這凸顯了靈活的報銷策略以及與醫療專業人員密切合作的必要性。該地區的市場參與企業通常優先考慮產生清晰的真實世界數據（REW），並強調能夠引起專科醫生和基層醫療醫生共鳴的價值提案。

競爭格局分析，重點在於決定過敏疫苗商業化領導地位的科學差異化、策略夥伴關係和營運能力。

過敏疫苗領域的競爭格局由成熟的生物製藥研發公司、專業的免疫療法公司和新興的生物技術創新公司組成。在這種競爭環境下，差異化源自於多種因素。具體而言，這些因素包括獨特的抗原和佐劑平台、顯著提升患者便利性的劑型，以及致力於提供全面證據以支持長期安全性和有效性的承諾。擁有從製劑到分銷垂直整合能力的公司可以透過縮短供應時間和改善利潤率管理來獲得競爭優勢。另一方面，專注於特定適應症和提供優質患者服務的專業公司也能有效參與競爭。

為企業主管提供實用建議，幫助他們整合科學創新、供應鏈韌性和以患者為中心的商業化，以建立永續的競爭優勢。

過敏疫苗領域的領導企業應優先考慮在科學研究、供應鏈韌性以及以患者為中心的交付模式等方面進行合作投資。首先，投資於能夠提供可證實的安全性和持久性優勢的技術平台，仍然是建立臨床信譽的最可靠途徑。此類投資必須輔以早期規劃，以產生滿足監管機構和支付方要求的證據，包括真實世界資料收集和長期安全性監測方案。

透過對關鍵相關人員的訪談、嚴格的二次分析和基於情境的考慮，調查方法產生了與過敏疫苗相關人員的決策直接相關的見解。

本研究途徑結合了系統性的證據整合、相關人員訪談和質性營運分析，旨在建構一個穩健且具決策意義的觀點。初步研究包括與臨床專家、供應鏈專家和商業領袖進行深入對話，以了解他們在用藥偏好、推廣障礙和分銷挑戰方面的細微見解。後續研究整合了同行評審文獻、監管指南和公開文件，以基於檢驗的技術和政策資訊來源得出見解。

總之，綜合分析強調了整合科學、營運和相關人員策略的必要性，以將過敏疫苗創新與持久的患者影響聯繫起來。

總而言之，過敏疫苗領域正從漸進式改進邁向變革性時代，其特點是免疫靶向性增強、給藥方式多樣化以及臨床實踐中對疫苗性能的更高期望。臨床進展和給藥方式的創新相結合，為提高疫苗可及性、改善遵守用藥和增強安全性創造了機遇，但也增加了整合證據和建立跨部門系統的難度。那些能夠將科學差異化、穩健的運作結構和以患者為中心的給藥模式結合的機構，將更有能力產生長期影響。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 過敏疫苗市場：依疫苗類型分類

  • 單抗原
  • 多種抗原

第9章 過敏疫苗市場：依給藥途徑分類

  • 皮下免疫療法
    • 加速管理
    • 標準劑量
  • 舌下免疫療法
    • 滴
    • 藥片

第10章：過敏疫苗市場：依目標過敏原分類

  • 常年性過敏原
    • 動物皮屑
    • 塵蟎
  • 季節性過敏原
    • 模具
    • 花粉

第11章 過敏疫苗市場：依技術分類

  • 重組
  • 常規萃取方法

第12章：過敏疫苗市場：依患者年齡層別分類

  • 成人版
  • 老年人
  • 兒童

第13章 過敏疫苗市場：依最終用戶分類

  • 診所
  • 家庭醫療保健
  • 醫院

第14章 過敏疫苗市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第15章 過敏疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 過敏疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 過敏疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國：過敏疫苗市場

第19章 中國：過敏疫苗市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Adamis Pharmaceuticals Corporation
  • ALK-Abello A/S
  • Allergopharma GmbH & Co. KG
  • Allergy Therapeutics plc
  • Anergis SA
  • Biomay AG
  • Boehringer Ingelheim International GmbH
  • Circassia Group plc
  • CSL Limited
  • DBV Technologies SA
  • HAL Allergy BV
  • Inmunotek SL
  • Jubilant HollisterStier LLC
  • Laboratorios LETI, SLU
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Stallergenes Greer International AG
  • Thermo Fisher Scientific Inc.
  • Torii Pharmaceutical Co., Ltd.
  • Zhejian Wolwo Bio-pharmaceutical Co., Ltd.
  • Zydus Lifesciences Ltd.
Product Code: MRR-436901065A74

The Allergy Vaccine Market was valued at USD 1.60 billion in 2025 and is projected to grow to USD 1.79 billion in 2026, with a CAGR of 13.58%, reaching USD 3.90 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.60 billion
Estimated Year [2026] USD 1.79 billion
Forecast Year [2032] USD 3.90 billion
CAGR (%) 13.58%

A concise introduction framing clinical, operational, and commercial considerations that shape successful allergy vaccine development and adoption

The allergy vaccine landscape is undergoing a period of concentrated innovation that intersects advances in immunobiology, delivery technology, and payer expectations. Recent clinical progress has sharpened the focus on durable patient outcomes and safety profiles, while parallel improvements in formulation and administration broaden the range of viable therapeutic models. As a result, stakeholders must evaluate not only scientific merit but also practical considerations such as patient adherence, clinical infrastructure, and regulatory pathways.

Strategic decision-making in this space now requires a multidimensional view that integrates clinical data, technology readiness, stakeholder preferences, and distribution realities. Researchers and commercial teams alike should adopt a perspective that treats product development and market access as interdependent activities. Transitioning from proof-of-concept to routine clinical use demands early alignment with clinicians, payers, and supply chain partners to ensure that promising candidates can be confidently positioned and efficiently delivered to patients.

This report begins by situating allergy vaccines within that broader healthcare ecosystem, highlighting the clinical and operational levers that will determine which technologies and models gain traction. Emphasis is placed on actionable intelligence: clear implications for development priorities, stakeholder engagement strategies, and preparatory investments that increase the likelihood of successful adoption in diverse care settings.

An analysis of converging scientific, patient experience, and digital health trends that are redefining how allergy vaccines are developed, delivered, and evaluated

The allergy vaccine sector is experiencing transformative shifts driven by converging trends in immunotherapy science, patient centricity, and digital health enablement. Immunological insight has advanced to a point where antigen design and adjuvant selection can be tailored to elicit targeted, durable responses while minimizing adverse events. Simultaneously, patient expectations have evolved: ease of use, reduced clinic visits, and more predictable side-effect profiles are becoming essential components of product value propositions.

Technological innovation in delivery formats is reshaping care pathways. Novel administration approaches are expanding the settings in which immunotherapy can be safely and effectively delivered, enabling greater involvement of ambulatory clinics and home-based care. Digital tools are augmenting adherence monitoring, remote symptom tracking, and virtual clinician follow-up, which together reduce friction in long-term treatment regimens. From a regulatory and payer standpoint, increased emphasis on real-world effectiveness and safety data is shifting how value is measured and reimbursed, prompting developers to embed evidence-generation strategies into development plans early.

Taken together, these shifts favor integrated strategies that combine scientific differentiation with practical delivery and evidence plans. Organizations that orchestrate product attributes, patient experience, and post-market data collection cohesively will be best positioned to capture clinical adoption and stakeholder trust in a rapidly evolving landscape.

How recent tariff dynamics are reshaping supply chain resilience, sourcing strategies, and strategic decision-making across allergy vaccine production and distribution

The imposition and evolution of tariffs in 2025 have introduced a complex set of operational and strategic consequences for organizations operating in the allergy vaccine ecosystem. Tariff-related cost pressures reverberate across supply chains, influencing procurement decisions for raw materials, excipients, and manufacturing equipment. Producers and distributors must therefore reassess supplier footprints and inventory strategies to mitigate exposure to sudden cost shifts and to preserve reliable access to critical inputs.

In response, many organizations are exploring supply chain diversification, including dual-sourcing strategies and geographically balanced manufacturing footprints that can cushion the operational impact of tariff fluctuations. This also drives greater attention to nearshoring possibilities and contractual protections that allocate tariff risk more equitably between buyers and suppliers. Additionally, procurement teams are negotiating more detailed tariff-trigger clauses and building scenario-based cost models to support pricing and contracting decisions.

Beyond procurement, tariffs influence strategic priorities such as where to locate clinical manufacturing and commercialization activities, and how to structure global distribution agreements. Stakeholders are increasingly prioritizing resilience and agility over the lowest-cost sourcing alone. To remain competitive, companies are investing in cost-to-serve analyses and operational safeguards that enable them to adapt quickly to policy-driven cost changes while maintaining continuity of supply and protecting margins.

In-depth segmentation insights explaining how administration routes, allergen focus, vaccine formats, distribution methods, and user settings drive differentiated clinical and commercial strategies

Segment-level dynamics illuminate different pathways to clinical and commercial success, with routes of administration, allergen targets, vaccine formats, distribution channels, technology platforms, patient cohorts, and end users each presenting specific operational and value-creation implications. Route of administration distinctions between subcutaneous immunotherapy and sublingual immunotherapy alter clinical workflows and patient adherence expectations: subcutaneous approaches that employ accelerated dosing pathways demand robust clinic infrastructure and trained providers, while standard dosing schedules emphasize longitudinal adherence programs. Sublingual options, including both drops and tablets, expand the potential for at-home initiation and ongoing administration, shifting the emphasis toward patient education and remote monitoring to ensure sustained outcomes.

Allergen targeting differentiates product positioning and clinical utility. Perennial allergens such as animal dander and dust mite generate steady, year-round symptom burdens that favor long-term maintenance strategies and close coordination with primary care and specialty clinics. Seasonal allergens including molds and pollen produce more episodic demand and may align with seasonal treatment campaigns and targeted outreach, which affects inventory cadence and promotional timing. Vaccine type-monovalent versus polyvalent-also informs development complexity and commercial messaging. Monovalent formulations can deliver focused efficacy for a single dominant allergen, while polyvalent products must balance breadth of coverage with formulation stability and regulatory complexity.

Distribution channel dynamics are central to access and adherence. Hospital pharmacies, online pharmacies, and retail pharmacies each provide distinct pathways to patients, with hospital pharmacies serving complex or supervised administration needs, online pharmacies offering convenience and adherence support tools, and retail pharmacies enabling broad geographic reach and point-of-care interactions. Technology choices, including recombinant platforms versus traditional extract-based approaches, carry implications for manufacturing scalability, regulatory dossier composition, and differentiation potential. Patient age group segmentation-adult, geriatric, and pediatric-requires tailored safety, dosing, and adherence strategies that influence trial design and post-market services. Finally, end users such as clinics, home healthcare providers, and hospitals determine the operational requirements for product delivery, staff training, and supportive services, shaping overall commercialization approaches.

Regional dynamics and practical considerations that require modular global strategies to align regulatory, payer, and distribution priorities across diverse healthcare landscapes

Regional patterns in demand, regulatory nuance, and healthcare delivery frameworks meaningfully alter how allergy vaccine initiatives must be executed across geographies. In the Americas, healthcare systems combine private and public payer structures with diverse provider networks, which emphasizes the need for flexible reimbursement strategies and strong clinician engagement. Market entrants in this region often prioritize clear real-world evidence generation and value arguments that resonate with both specialist and primary care audiences.

Within Europe, Middle East & Africa, regulatory heterogeneity and varied care delivery models require careful alignment of clinical dossiers and commercial approaches with local standards and procurement practices. Multi-country launches in this region benefit from adaptive regulatory strategies and partnerships with regional distribution and clinical champions. The Asia-Pacific region presents a combination of high-volume opportunity and varied regulatory maturity; it also features a strong emphasis on scalable manufacturing, regional clinical collaborations, and culturally adapted patient engagement strategies. Across all regions, cross-border supply chain planning, local stakeholder networks, and targeted evidence portfolios are essential to translate scientific advances into durable access and uptake.

Taken together, regional insights point to a pragmatic requirement: global plans must be modular and regionally configurable, enabling rapid localization of pricing, regulatory filings, and distribution while preserving the coherence of the broader product narrative and evidence strategy.

Competitive landscape analysis highlighting scientific differentiation, strategic partnerships, and operational capabilities that determine leadership in allergy vaccine commercialization

Competitive dynamics in the allergy vaccine space reflect a mix of established biologics developers, specialty immunotherapy firms, and emerging biotechnology innovators. Across this competitive set, differentiation arises from multiple sources: unique antigen or adjuvant platforms, delivery formats that materially improve patient convenience, and comprehensive evidence-generation commitments that speak to long-term safety and effectiveness. Organizations with vertically integrated capabilities from formulation through distribution can capture advantage by reducing time-to-supply and improving margin control, while specialist firms can compete effectively by focusing on niche indications or superior patient-facing services.

Strategic partnerships and licensing arrangements are prevalent as companies seek to combine scientific strengths with commercialization reach. Collaborations with contract manufacturing organizations and distribution partners help balance capital intensity with the need for rapid scale-up. Additionally, alliances with digital health vendors and homecare providers are increasingly important to support adherence, remote monitoring, and patient education. Investors and strategic acquirers are attentive to companies that demonstrate a clear pathway to durable clinical differentiation and robust, defensible evidence packages that will facilitate payer acceptance and clinician adoption.

Organizational agility remains a key competitive capability. Firms that can rapidly iterate on formulations, pivot distribution strategies, and deploy targeted evidence generation for specific patient cohorts will be better positioned to capture commercial opportunities and respond to shifting policy environments.

Actionable recommendations for executives to synchronize scientific innovation, supply chain resilience, and patient-centric commercialization for sustained competitive advantage

Leaders in the allergy vaccine sector should prioritize coordinated investments across science, supply chain resilience, and patient-centric delivery models. First, investment in technology platforms that offer demonstrable safety and durability advantages will remain the most reliable route to clinical credibility. Such investments should be paired with early planning for evidence generation that satisfies both regulatory agencies and payers, including protocols for real-world data collection and long-term safety monitoring.

Second, supply chain strategy must be treated as a strategic asset. Diversifying suppliers, considering regional manufacturing hubs, and embedding contractual protections against policy-driven cost shocks will reduce operational risk. In parallel, developing distribution partnerships that enable flexible pathways-ranging from hospital-based administration to home delivery supported by telehealth-will expand reach while improving adherence. Third, commercialization approaches should be patient-centric: simplifying administration, reducing clinic visit burdens, and integrating digital adherence supports will create clearer value propositions for clinicians and payers alike. Finally, organizations should cultivate collaborative relationships with clinicians, payers, and patient advocacy groups to co-design access strategies that reflect the real-world needs of those receiving immunotherapy.

By aligning scientific ambition with operational readiness and stakeholder engagement, industry leaders can convert innovation into durable patient benefits and sustainable commercial outcomes.

Research methodology that integrates primary stakeholder interviews, rigorous secondary analysis, and scenario-based examination to generate decision-ready insights for allergy vaccine stakeholders

The research approach combines systematic evidence synthesis, stakeholder interviews, and qualitative operational analysis to create a robust, decision-ready perspective. Primary research included in-depth conversations with clinical experts, supply chain professionals, and commercial leaders to capture nuanced views on administration preferences, adoption barriers, and distribution challenges. Secondary research integrated peer-reviewed literature, regulatory guidance, and public filings to ground insights in verified technical and policy sources.

Analytical methods focused on cross-segmentation comparison and scenario-based stress testing. Segmentation analyses examined how routes of administration, allergen targets, vaccine formats, distribution channels, technology platforms, patient age groups, and end-user settings interact to affect clinical adoption and operational feasibility. Scenario analysis explored the operational consequences of supply chain disruptions and policy shifts, evaluating mitigation strategies for procurement, manufacturing, and distribution. The methodology emphasized transparency in assumptions, triangulation of qualitative and quantitative inputs, and identification of actionable implications for clinical development and commercialization stakeholders.

This combination of evidence sources and analytical frameworks supports pragmatic recommendations that account for scientific promise, operational constraints, and stakeholder incentives across different geographies and delivery settings.

Concluding synthesis underscoring the need for integrated scientific, operational, and stakeholder strategies to translate allergy vaccine innovation into sustained patient impact

In sum, the allergy vaccine domain is transitioning from incremental enhancements to a more transformative era characterized by improved immunological targeting, diversified delivery options, and heightened expectations for real-world performance. Clinical advances and delivery innovations together create opportunities to expand access, improve adherence, and enhance safety profiles, but they also raise the bar for integrated evidence generation and cross-functional readiness. Organizations that couple scientific differentiation with resilient operations and patient-centric delivery models will be positioned to realize long-term impact.

Strategic emphasis should be placed on modular global planning, robust supply chain design, and deliberate engagement with clinicians and payers to build credible value propositions. As the policy environment and payer expectations evolve, embedding real-world data collection and adaptive commercial strategies into development plans will be essential. Ultimately, converting scientific potential into sustainable patient benefit requires a holistic approach that aligns product attributes, service models, and stakeholder incentives across the lifecycle of development and commercialization.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Allergy Vaccine Market, by Vaccine Type

  • 8.1. Monovalent
  • 8.2. Polyvalent

9. Allergy Vaccine Market, by Route Of Administration

  • 9.1. Subcutaneous Immunotherapy
    • 9.1.1. Accelerated Doses
    • 9.1.2. Standard Doses
  • 9.2. Sublingual Immunotherapy
    • 9.2.1. Drops
    • 9.2.2. Tablets

10. Allergy Vaccine Market, by Allergens Targeted

  • 10.1. Perennial Allergens
    • 10.1.1. Animal Dander
    • 10.1.2. Dust Mite
  • 10.2. Seasonal Allergens
    • 10.2.1. Molds
    • 10.2.2. Pollen

11. Allergy Vaccine Market, by Technology

  • 11.1. Recombinant
  • 11.2. Traditional Extract

12. Allergy Vaccine Market, by Patient Age Group

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Allergy Vaccine Market, by End User

  • 13.1. Clinics
  • 13.2. Home Healthcare
  • 13.3. Hospitals

14. Allergy Vaccine Market, by Distribution Channel

  • 14.1. Hospital Pharmacies
  • 14.2. Online Pharmacies
  • 14.3. Retail Pharmacies

15. Allergy Vaccine Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Allergy Vaccine Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Allergy Vaccine Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Allergy Vaccine Market

19. China Allergy Vaccine Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Adamis Pharmaceuticals Corporation
  • 20.6. ALK-Abello A/S
  • 20.7. Allergopharma GmbH & Co. KG
  • 20.8. Allergy Therapeutics plc
  • 20.9. Anergis SA
  • 20.10. Biomay AG
  • 20.11. Boehringer Ingelheim International GmbH
  • 20.12. Circassia Group plc
  • 20.13. CSL Limited
  • 20.14. DBV Technologies S.A.
  • 20.15. HAL Allergy B.V.
  • 20.16. Inmunotek S.L.
  • 20.17. Jubilant HollisterStier LLC
  • 20.18. Laboratorios LETI, S.L.U.
  • 20.19. Merck KGaA
  • 20.20. Mitsubishi Tanabe Pharma Corporation
  • 20.21. Novartis International AG
  • 20.22. Pfizer Inc.
  • 20.23. Regeneron Pharmaceuticals, Inc.
  • 20.24. Sanofi S.A.
  • 20.25. Stallergenes Greer International AG
  • 20.26. Thermo Fisher Scientific Inc.
  • 20.27. Torii Pharmaceutical Co., Ltd.
  • 20.28. Zhejian Wolwo Bio-pharmaceutical Co., Ltd.
  • 20.29. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ALLERGY VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ALLERGY VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ALLERGY VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ALLERGY VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ALLERGY VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ALLERGY VACCINE MARKET SIZE, BY MONOVALENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ALLERGY VACCINE MARKET SIZE, BY MONOVALENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALLERGY VACCINE MARKET SIZE, BY MONOVALENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ALLERGY VACCINE MARKET SIZE, BY POLYVALENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALLERGY VACCINE MARKET SIZE, BY POLYVALENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ALLERGY VACCINE MARKET SIZE, BY POLYVALENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ACCELERATED DOSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ACCELERATED DOSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ACCELERATED DOSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ALLERGY VACCINE MARKET SIZE, BY STANDARD DOSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ALLERGY VACCINE MARKET SIZE, BY STANDARD DOSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALLERGY VACCINE MARKET SIZE, BY STANDARD DOSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ALLERGY VACCINE MARKET SIZE, BY DROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ALLERGY VACCINE MARKET SIZE, BY DROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ALLERGY VACCINE MARKET SIZE, BY DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ALLERGY VACCINE MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ALLERGY VACCINE MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALLERGY VACCINE MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ANIMAL DANDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ANIMAL DANDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ANIMAL DANDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ALLERGY VACCINE MARKET SIZE, BY DUST MITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ALLERGY VACCINE MARKET SIZE, BY DUST MITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ALLERGY VACCINE MARKET SIZE, BY DUST MITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ALLERGY VACCINE MARKET SIZE, BY MOLDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ALLERGY VACCINE MARKET SIZE, BY MOLDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ALLERGY VACCINE MARKET SIZE, BY MOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ALLERGY VACCINE MARKET SIZE, BY POLLEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALLERGY VACCINE MARKET SIZE, BY POLLEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ALLERGY VACCINE MARKET SIZE, BY POLLEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ALLERGY VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ALLERGY VACCINE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ALLERGY VACCINE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ALLERGY VACCINE MARKET SIZE, BY TRADITIONAL EXTRACT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ALLERGY VACCINE MARKET SIZE, BY TRADITIONAL EXTRACT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ALLERGY VACCINE MARKET SIZE, BY TRADITIONAL EXTRACT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ALLERGY VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ALLERGY VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ALLERGY VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ALLERGY VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ALLERGY VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ALLERGY VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ALLERGY VACCINE MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ALLERGY VACCINE MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ALLERGY VACCINE MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ALLERGY VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ALLERGY VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ALLERGY VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ALLERGY VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ALLERGY VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ALLERGY VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ALLERGY VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ALLERGY VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ALLERGY VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ALLERGY VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ALLERGY VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL ALLERGY VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. GCC ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. GCC ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. GCC ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. GCC ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
  • TABLE 204. GCC ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 205. GCC ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GCC ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. GCC ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. G7 ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. G7 ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. G7 ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. G7 ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. G7 ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
  • TABLE 240. G7 ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 241. G7 ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 242. G7 ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. G7 ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. G7 ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. G7 ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. NATO ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. NATO ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. NATO ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. NATO ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. NATO ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. NATO ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
  • TABLE 252. NATO ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 253. NATO ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 254. NATO ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. NATO ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 256. NATO ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. NATO ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)